In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Combinatorial Recombinations

Executive Summary

Pharmacopeia's deal with Schering-Plough is one of the very few rich alliances in a technology area in which only Affymax has proven that it can attract significant big-company funding. Selectide's acquisition by Marion Merrell Dow raises questions about how much this technology can be partnered: many potentialpartners believe they can develop the technology on their own, or if they can't, want to use the start-up's libraries against all of their targets--a virtual acquisition. Real acquisition might be the best option.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts